Mieloma múltiple en Chile: Respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticos
Background The treatment of choice of newly diagnosed multiple myeloma (NDMM) is an induction with proteasome inhibitors followed autologous stem cell transplantation (HSCT). Since 2013, the treatment of these patients in the public system is based on CTD (cyclophosphamide, thalidomide, and dexamet...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2019
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019001201561 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:scielo:S0034-98872019001201561 |
|---|---|
| record_format |
dspace |
| spelling |
oai:scielo:S0034-988720190012015612020-07-22Mieloma múltiple en Chile: Respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticosPEÑA,CAMILAROJAS-VALLEJOS,JORGEESPINOZA,MARCELADONOSO,JAVIERASOTO,PABLOCARDEMIL,DANIELAARANDA,SANDRACONTRERAS,CAROLINAVERGARA,CARMEN GLORIALA ROCCA,GABRIELOSORIO,ROCÍOLÓPEZ-VIDAL,HERNÁNCHANDÍA,MAURICIOROJAS,CHRISTINE Bortezomib Dexamethasone Hematopoietic Stem Cell Transplantation Multiple Myeloma Background The treatment of choice of newly diagnosed multiple myeloma (NDMM) is an induction with proteasome inhibitors followed autologous stem cell transplantation (HSCT). Since 2013, the treatment of these patients in the public system is based on CTD (cyclophosphamide, thalidomide, and dexamethasone). Aim To evaluate the response rates achieved with CTD, and the results of HSCT in patients with NDMM in the public setting. Material and Methods Data from patients considered as candidates for HSCT from different centers of the National Adult Antineoplastic Drug Program (PANDA, for its acronym in Spanish), diagnosed between 2013 and 2017, was analyzed. The response to treatment of first and second lines of treatment was evaluated, in addition to the results of HSCT. An optimal Response was defined as the sum of strict complete remission, complete remission and very good partial response (sCR, CR and VGPR). Results One hundred and seventy-seven patients were analyzed, 54% women, and 53% with IgG multiple myeloma. Information about the international staging system was retrieved in 127 patients (71%). Seventeen percent were ISS I, 22% in ISS II and 32% ISS III. CTD was used as first treatment in 106 patients (60%), and cyclophosphamide, bortezomib and dexamethasone (CyBorD) in 13 (7%). As first line, CTD had an overall response of 50.9%, and CyBorD of 76.9%. Thirty patients were treated with bortezomib as second line treatment. Forty patients (22%) underwent HSCT. The 5-year Overall Survival (OS) in transplanted patients and non-transplanted patients was 100 and 62% respectively (p < 0.01). Conclusions The response rate achieved by CTD in these patients is suboptimal. The response to CyBorD was better.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.147 n.12 20192019-12-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019001201561es10.4067/S0034-98872019001201561 |
| institution |
Scielo Chile |
| collection |
Scielo Chile |
| language |
Spanish / Castilian |
| topic |
Bortezomib Dexamethasone Hematopoietic Stem Cell Transplantation Multiple Myeloma |
| spellingShingle |
Bortezomib Dexamethasone Hematopoietic Stem Cell Transplantation Multiple Myeloma PEÑA,CAMILA ROJAS-VALLEJOS,JORGE ESPINOZA,MARCELA DONOSO,JAVIERA SOTO,PABLO CARDEMIL,DANIELA ARANDA,SANDRA CONTRERAS,CAROLINA VERGARA,CARMEN GLORIA LA ROCCA,GABRIEL OSORIO,ROCÍO LÓPEZ-VIDAL,HERNÁN CHANDÍA,MAURICIO ROJAS,CHRISTINE Mieloma múltiple en Chile: Respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticos |
| description |
Background The treatment of choice of newly diagnosed multiple myeloma (NDMM) is an induction with proteasome inhibitors followed autologous stem cell transplantation (HSCT). Since 2013, the treatment of these patients in the public system is based on CTD (cyclophosphamide, thalidomide, and dexamethasone). Aim To evaluate the response rates achieved with CTD, and the results of HSCT in patients with NDMM in the public setting. Material and Methods Data from patients considered as candidates for HSCT from different centers of the National Adult Antineoplastic Drug Program (PANDA, for its acronym in Spanish), diagnosed between 2013 and 2017, was analyzed. The response to treatment of first and second lines of treatment was evaluated, in addition to the results of HSCT. An optimal Response was defined as the sum of strict complete remission, complete remission and very good partial response (sCR, CR and VGPR). Results One hundred and seventy-seven patients were analyzed, 54% women, and 53% with IgG multiple myeloma. Information about the international staging system was retrieved in 127 patients (71%). Seventeen percent were ISS I, 22% in ISS II and 32% ISS III. CTD was used as first treatment in 106 patients (60%), and cyclophosphamide, bortezomib and dexamethasone (CyBorD) in 13 (7%). As first line, CTD had an overall response of 50.9%, and CyBorD of 76.9%. Thirty patients were treated with bortezomib as second line treatment. Forty patients (22%) underwent HSCT. The 5-year Overall Survival (OS) in transplanted patients and non-transplanted patients was 100 and 62% respectively (p < 0.01). Conclusions The response rate achieved by CTD in these patients is suboptimal. The response to CyBorD was better. |
| author |
PEÑA,CAMILA ROJAS-VALLEJOS,JORGE ESPINOZA,MARCELA DONOSO,JAVIERA SOTO,PABLO CARDEMIL,DANIELA ARANDA,SANDRA CONTRERAS,CAROLINA VERGARA,CARMEN GLORIA LA ROCCA,GABRIEL OSORIO,ROCÍO LÓPEZ-VIDAL,HERNÁN CHANDÍA,MAURICIO ROJAS,CHRISTINE |
| author_facet |
PEÑA,CAMILA ROJAS-VALLEJOS,JORGE ESPINOZA,MARCELA DONOSO,JAVIERA SOTO,PABLO CARDEMIL,DANIELA ARANDA,SANDRA CONTRERAS,CAROLINA VERGARA,CARMEN GLORIA LA ROCCA,GABRIEL OSORIO,ROCÍO LÓPEZ-VIDAL,HERNÁN CHANDÍA,MAURICIO ROJAS,CHRISTINE |
| author_sort |
PEÑA,CAMILA |
| title |
Mieloma múltiple en Chile: Respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticos |
| title_short |
Mieloma múltiple en Chile: Respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticos |
| title_full |
Mieloma múltiple en Chile: Respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticos |
| title_fullStr |
Mieloma múltiple en Chile: Respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticos |
| title_full_unstemmed |
Mieloma múltiple en Chile: Respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticos |
| title_sort |
mieloma múltiple en chile: respuesta a tratamiento en pacientes con mieloma múltiple elegibles para trasplante autólogo de progenitores hematopoyéticos |
| publisher |
Sociedad Médica de Santiago |
| publishDate |
2019 |
| url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019001201561 |
| work_keys_str_mv |
AT penacamila mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT rojasvallejosjorge mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT espinozamarcela mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT donosojaviera mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT sotopablo mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT cardemildaniela mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT arandasandra mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT contrerascarolina mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT vergaracarmengloria mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT laroccagabriel mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT osoriorocio mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT lopezvidalhernan mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT chandiamauricio mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos AT rojaschristine mielomamultipleenchilerespuestaatratamientoenpacientesconmielomamultipleelegiblesparatrasplanteautologodeprogenitoreshematopoyeticos |
| _version_ |
1718437096975237120 |